secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dogwood Therapeutics, Inc. (DWTX)
CIK:        0001818844
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001558370-25-004150
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dogwood Therapeutics Q4 2024 net loss $8.2M; cash $14.8M; Halneuron Phase 2b interim data expected Q4 2025
--------------------------------------------------------------------------------

- Q4 2024 net loss $8.2M ($6.29/share) vs $1.1M ($1.43/share) in Q4 2023; FY net loss $12.9M ($12.52/share) vs $5.3M ($7.05/share).
- Cash $14.8M at Dec 31, 2024; $4.8M capital raise and conversion of $19.5M debt to equity extend runway through Q1 2026.
- Halneuron Phase 2b CINP trial dosing commenced; interim data readout expected Q4 2025.
- Largest shareholder converted $19.5M loan to equity, strengthening balance sheet.
- Exploring partnerships for IMC-2 (Long-COVID) and IMC-1 (fibromyalgia); update on IMC-1 expected Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818844/000155837025004150/0001558370-25-004150-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818844/000155837025004150/dwtx-20250331x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-004150

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer